Corvus Raises $201M and Reports 72% EASI Reduction in Phase I AD Trial
Corvus closed an upsized offering of 9,085,778 shares at $22.15, raising $201.2M for working capital and R&D across Phase 3 PTCL and Phase 2 programs. It reported Phase I soquelitinib data showing a 72% mean EASI reduction at eight weeks with 75% of patients achieving EASI75.
1. Offering Terms and Gross Proceeds
Corvus Pharmaceuticals closed an upsized underwritten public offering of 9,085,778 shares of its common stock, reflecting full exercise of the underwriters’ option to purchase an additional 1,185,101 shares. The shares were sold at $22.15 each, generating approximately $201.2 million in gross proceeds before underwriting discounts, commissions and estimated offering expenses. Jefferies and Goldman Sachs & Co. LLC served as lead book-running managers, with Mizuho as bookrunner and Ladenburg Thalmann as co-manager.
2. Planned Use of Net Proceeds
Management expects to deploy the net proceeds toward working capital and general corporate purposes, including capital expenditures and research and development. R&D priorities encompass the ongoing Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma and Phase 2 studies in atopic dermatitis, hidradenitis suppurativa and asthma. Additional allocations include support for sales and marketing initiatives and administrative overhead, positioning the company to advance its mid-stage pipeline through key clinical inflection points.
3. Regulatory Shelf and Prospectus Filings
The securities were offered under a shelf registration statement on Form S-3 (File No. 333-281318) declared effective by the SEC on August 15, 2024, and a subsequent Rule 462(b) registration filed on January 21, 2026, which became automatically effective upon submission. A final prospectus supplement and accompanying base prospectus have been filed with the SEC and are accessible via the SEC’s website. Physical copies may be obtained from the prospectus departments of Jefferies LLC and Goldman Sachs & Co. LLC as detailed in the company’s announcement.
4. Strategic and Investor Implications
By securing over $200 million in new capital, Corvus extends its cash runway into the fourth quarter of 2026, according to management’s projections. This funding milestone reduces near-term refinancing risk and supports enrollment expansion in upcoming international trials. For investors, progress on soquelitinib’s clinical development and the company’s ability to advance multiple indications without immediate equity dilution enhance visibility on value-creating catalysts through 2026, including a planned interim futility analysis in the lymphoma study and Phase II readouts in atopic dermatitis.